Whalesbook
Dr. Reddy's Laboratories has launched its generic Semaglutide Injection in Canada, making it the first G7 nation to have a generic version of the popular diabetes and weight loss drug. Health Canada approved the launch on April 28, 2026. This move comes after a key Canadian patent for Novo Nordisk's Ozempic lapsed due to missed maintenance fee payments dating back to 2018, removing potential market exclusivity.
The company, with a market capitalization around $11.4 billion USD, is now set to offer a more affordable alternative to Ozempic. Dr. Reddy's CEO Erez Israeli described the planned pricing as "very healthy," though he noted initial costs might be higher due to limited competition. The company's stock recently traded around ₹1,336.70 (approximately $16 USD) on May 14, 2026, within its 52-week range of $12.19 to $16.17 USD.
This launch targets the rapidly expanding GLP-1 market, which is projected to reach $190 billion globally by 2035. In Canada, spending on antidiabetic drugs was $2.7 billion in 2021, with GLP-1 agonists making up 25% of that. Ozempic alone generated substantial sales in Canada, reaching $2.9 billion in 2025. Novo Nordisk, the market leader with a 55.1% share, faces a significant challenge as its Canadian patent protection expired years before U.S. generics are expected in 2032. Competitors like Eli Lilly also hold strong positions. Generic drugs in Canada typically cost 45-90% less than brand-name versions. Dr. Reddy's launch, along with a subsequent approval for Apotex, signals a shift, with seven other generic submissions pending. Dr. Reddy's itself has shown strong financial growth, with a 14.4% CAGR from FY2021 to FY2025 and an improved operating margin of 22.4% in FY2025.
Despite the opportunity, Dr. Reddy's faces potential price erosion due to intense GLP-1 competition, which could affect profit margins. Analysts hold mixed views, with a consensus rating of "Hold" and an average target price of $16.90 USD, suggesting cautious optimism. Notably, Goldman Sachs reportedly downgraded Dr. Reddy's to "Sell" in April 2026, citing concerns over generic Ozempic. This bearish view, coupled with the stock's volatility and a recent "Hold" downgrade by MarketsMOJO in May 2026, highlights the risks in this competitive market. However, Dr. Reddy's strong balance sheet and low debt provide a solid foundation.
Dr. Reddy's expects future growth from new product launches, including this generic Semaglutide and the arthritis drug Abatacept, anticipated around FY28. The company sees healthy growth from its operations in India, Europe, and emerging markets, with expectations for margin improvements through better product mix and cost management. The expanding global GLP-1 market and Canada's high diabetes rates create substantial demand. The company's success will depend on its pricing strategy and ability to gain market share. While brokerage consensus suggests potential upside, the "Sell" recommendation from Goldman Sachs warrants close attention as generic competition continues to grow worldwide.